Purpose. - Assessment of early therapeutic response is essential to guide therapeutic management in patients with advanced leiomyosarcoma (LMS). We compared the predictive values of various 18F-FDG PET-CT-derived metabolic parameters, SUVmax, SUVpeak, metabolic tumor volume (MTV) and total lesion glycolysis (TLG). Methods. - A total of 64 patients with LMS who underwent FDG PET/CT before and 6 weeks after the initiation of treatment were retrospectively analyzed. We determined SUVmax, SUVpeak, MTV, and TLG by segmentation to compare their predictive value for 9-month progression-free survival and overall survival. These parameters were dichotomized using the optimal threshold according to the area under the ROC (Receiver Operation Characteristic) curve and evaluated using a Cox model. Overall and progression-free survival analyses were performed using the Kaplan Meier model. Results. - SUVmax showed greater accuracy than TLG or MTV in ROC analysis (area under the curve, AUC, 0.680, 0.677, and 0.675, respectively). The cutoff values derived from the AUC data were SUVmax 4.7, TLG 37.46, and MTV 25 cm(3). After dichotomization by threshold values, MTV was the most significant predictor compared with SUVmax and TLG (P = 0.000165, P= 0.007, and P = 0.001, respectively). In early therapeutic evaluation at 6 weeks, delta SUVpeak and PERCIST metabolic response were significantly correlated with progression-free survival (P = 0.008 and 0.035, respectively). Conclusion. - Baseline SUVmax, MTV and TGL were predictive of overall survival, delta SUVpeak and PERCIST response obtained by functional imaging in early therapeutic evaluation were significantly correlated with progression-free survival in advanced leiomyosarcoma patients. (C) 2021 Elsevier Masson SAS. All rights reserved.
展开▼
